Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2018
Financial Statements ReleaseJanuary 1-December 31, 2018 Progress from safety studies toward clinical proof-of-concept Highlights in January-December 2018: · Herantis Pharma ("Herantis") completed the patient enrolment in the Phase 1 clinical study of Lymfactin in February. · Phase 1-2 clinical study of CDNF expanded in February to the university hospitals of Helsinki and Lund in addition to Stockholm based on a favorable first safety evaluation. · Herantis announced in April positive interim results from its Phase 1 clinical study of Lymfactin® in the treatment of breast